Satraplatin

DB04996InvestigationalSmall molecule

Satraplatin is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy. As an investigation drug, it has... Food and Drug Administration (FDA) approval and is not available in retail pharmacies.

Mechanism: This drug binds to the DNA of cancer cells, inhibiting cell division.
Curator reviewed
Primary indication: Investigated for use/treatment in lung cancer, prostate cancer, and solid tumors.Curator reviewed
Formula / weight: C₁₀H₂₂Cl₂N₂O₄Pt · 500.283 g/mol (avg)
Code names: BMS-182751 · BMY-45594 · JM-216

Resolves to

Compound

UNII8D7B37T28GCAS129580-63-8ChEMBLCHEMBL3833367ChEBI85609PubChem123974

Clinical / RWD

RxNorm1733681ATCL01XA04

Structure

InChIKeyCKNPWBAXEKSCRG-UHFFFAOYSA-JSMILESN.[Cl-].[Cl-].[Pt+4].CC([O-])=O.CC([O-])=O.NC1CCCCC1

What you can answer from here — as of November 06, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

45Drug interactionsStructured to mechanism, not free text

17Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 4 drug categories

Which companies are running trials of Satraplatin, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account